Trial
NCT03639324
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Virginia Commonwealth University
Collaborators
Gilead Sciences
Condition
Chronic Lymphocytic Leukemia
Intervention
Dose combination 1-1
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09